SCHEMBL593275

SCHEMBL593275

Cc1cn(CCCCN2CCN(Cc3ccc(Cl)cc3Cl)CC2)c(=O)[nH]c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 2/20 0.49
POLB P06746 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
TK2 O00142 4/20 0.48
DRD2 P14416 1/20 0.47
DRD3 P35462 1/20 0.47
ADRA1D P25100 1/20 0.46
ADRA1A P35348 1/20 0.46
ADRA1B P35368 1/20 0.46
MAPK1 P28482 2/20 0.44
CYP2A13 Q16696 1/20 0.44
MAPT P10636 2/20 0.44
TSHR P16473 1/20 0.44
HTR1A P08908 1/20 0.43
HTR7 P34969 1/20 0.43
HTR6 P50406 1/20 0.43
HPGD P15428 1/20 0.43
TK1 P04183 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL591970 0.91 ALDH1A1 (0.52) ALDH1A1DRD2DRD3ADRA1DADRA1A
SCHEMBL593078 0.88 MAPK1 (0.54) ALDH1A1KDM4ETK2DRD2DRD3
SCHEMBL591669 0.87 DRD2 (0.47) SIGMAR1ALDH1A1KDM4EPOLBTDP1
SCHEMBL2350687 0.86 ADRA1A (0.56) ALDH1A1TK2DRD2DRD3ADRA1D
SCHEMBL593045 0.83 SIGMAR1 (0.49) SIGMAR1DRD2DRD3ADRA1DADRA1A
SCHEMBL593108 0.82 SIGMAR1 (0.51) SIGMAR1ALDH1A1KDM4EPOLBTDP1
SCHEMBL591628 0.82 MAPK1 (0.58) TK2DRD2DRD3ADRA1DADRA1A
SCHEMBL591722 0.82 HPGD (0.52) TK2DRD2DRD3ADRA1DADRA1A
SCHEMBL2352152 0.81 KDM4E (0.54) KDM4ETK2DRD2DRD3ADRA1D
SCHEMBL593713 0.81 HPGD (0.65) TK2ADRA1DADRA1AADRA1BMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828146-B1 SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBVIE DEUTSCHLAND (DE) 2014-11-05 EP claimed
EP-1828146-B1 SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBVIE DEUTSCHLAND (DE) 2014-11-05 EP disclosed
US-8114875-B2 Substituted N-heterocyclic compounds and their use as dopamine D3 receptor ligands ABBOTT GMBH & CO. KG (DE) 2012-02-14 US disclosed
US-20090054449-A1 Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands ABBOTT GMBH & CO. KG (DE) 2009-02-26 US disclosed
EP-1828146-A1 SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS Abbott GmbH & Co. KG (DE) 2007-09-05 EP disclosed
WO-2006066885-A1 SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBOTT GMBH & CO. KG (DE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054449-A1 Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands SLC6A3, DRD3, HTR3A SIGMAR1 185/4885ALDH1A1 1066/4885KDM4E 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.